As of 2026-10-05, the EV/EBITDA ratio of Nurix Therapeutics Inc (NRIX) is -6.58. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. NRIX's latest enterprise value is 2,318.22 mil USD. NRIX's TTM EBITDA according to its financial statements is -352.58 mil USD. Dividing these 2 quantities gives us the above NRIX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 15.8x - 16.9x | 16.2x |
| Forward P/E multiples | 18.8x - 22.1x | 20.4x |
| Fair Price | (63.22) - (56.63) | (61.43) |
| Upside | -375.0% - -346.3% | -367.2% |
| Date | EV/EBITDA |
| 2026-10-02 | -6.58 |
| 2026-10-01 | -6.68 |
| 2026-09-30 | -6.79 |
| 2026-09-29 | -6.78 |
| 2026-09-28 | -6.78 |
| 2026-09-25 | -6.58 |
| 2026-09-24 | -6.77 |
| 2026-09-23 | -6.84 |
| 2026-09-22 | -7.36 |
| 2026-09-21 | -7.29 |
| 2026-09-18 | -7.30 |
| 2026-09-17 | -7.31 |
| 2026-09-16 | -7.21 |
| 2026-09-15 | -7.12 |
| 2026-09-14 | -7.32 |
| 2026-09-11 | -7.20 |
| 2026-09-10 | -7.41 |
| 2026-09-09 | -7.54 |
| 2026-09-08 | -7.50 |
| 2026-09-04 | -7.50 |
| 2026-09-03 | -7.26 |
| 2026-09-02 | -7.41 |
| 2026-09-01 | -7.47 |
| 2026-08-31 | -7.40 |
| 2026-08-28 | -7.52 |
| 2026-08-27 | -7.72 |
| 2026-08-26 | -7.67 |
| 2026-08-25 | -7.74 |
| 2026-08-24 | -7.54 |
| 2026-08-21 | -7.67 |
| 2026-08-20 | -7.77 |
| 2026-08-19 | -7.99 |
| 2026-08-18 | -7.73 |
| 2026-08-17 | -7.81 |
| 2026-08-14 | -7.77 |
| 2026-08-13 | -7.81 |
| 2026-08-12 | -7.65 |
| 2026-08-11 | -7.45 |
| 2026-08-10 | -7.43 |
| 2026-08-07 | -7.32 |
| 2026-08-06 | -7.23 |
| 2026-08-05 | -7.20 |
| 2026-08-04 | -7.08 |
| 2026-08-03 | -6.64 |
| 2026-07-31 | -6.64 |
| 2026-07-30 | -6.75 |
| 2026-07-29 | -6.75 |
| 2026-07-28 | -6.92 |
| 2026-07-27 | -6.70 |
| 2026-07-24 | -6.69 |